This early study tests a gene therapy that delivers a protein called BDNF directly into the brain. The goal is to see if it is safe and can slow or prevent brain cell loss in people with early Alzheimer's or mild cognitive impairment. Only 12 participants will be enrolled in this…
Phase: PHASE1 • Sponsor: Mark Tuszynski • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC